NEW YORK (TheStreet) -- Shares of Amicus Therapeutics  (FOLD) - Get Report surged 14.9% to $6.54 in morning trading Monday after the company announced positive results of its experimental pill migalastat in patients with Fabry disease.

Amicus said patients showed improvements in heart size and had fewer disease-related events in comparison to similar patients treated with currently improved injectable therapies. This data supports earlier results from a Phase III study the company announced in August.

Fabry is a rare genetic disease that causes fat to build up in the body and causes pain, loss of hearing and cloudy eyes. It eventually leads to kidney failure, stroke and death.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Amicus announced the new data at the American Society of Nephrology annual meeting on Saturday.

For more on this story, read TheStreet's Adam Feuerstein's in-depth coverage here.

Image placeholder title

FOLD

data by

YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.